Man collapses in Oval Office on live TV as Trump announces obesity drug deal

Joseph Wilkinson, New York Daily News on Nov 6, 2025

By clicking submit, I authorize Arcamax and its affiliates to: (1) use, sell, and share my information for marketing purposes, including cross-context behavioral advertising, as described in our Privacy Policy , (2) add to information that I provide with other information like interests inferred from web page views, or data lawfully obtained from data brokers, such as past purchase or location data, or publicly available data, (3) contact me or enable others to contact me by email or other means with offers for different types of goods and services, and (4) retain my information while I am engaging with marketing messages that I receive and for a reasonable amount of time thereafter. I understand I can opt out at any time through an email that I receive, or by clicking here

A pharmaceutical executive collapsed in the Oval Office on live television Thursday during a press conference about the Trump administration’s deal to lower the cost of some obesity drugs.

The unnamed executive was standing in a group behind the podium while Eli Lilly CEO Dave Ricks spoke. As he began to fall, multiple men including Dr. Mehmet Oz attempted to hold him up before he collapsed to the floor.

“A representative with one of the companies fainted,” White House press secretary Karoline Leavitt said in a statement. “The White House Medical Unit quickly jumped into action, and the gentleman is OK.”

The press conference was briefly paused as reporters were ushered out of the Oval Office while the man received medical care. It resumed shortly afterward without him.

“One of the representatives of one of the companies got a little light-headed and so they went down,” President Trump said after the press was allowed back in. “He’s got doctor’s care, but he’s fine. So we had a little bit of an interruption. Sorry for that.”

Reports initially identified the fainting man as Novo Nordisk executive Gordon Findlay, but the company later said he was not in attendance for the presser.

Novo Nordisk sells the popular weight loss drug Wegovy, which costs about $500 per month for some doses and is rarely covered by insurance. Eli Lilly, whose execs were also in attendance, sells another popular obesity drug, Zepbound. The company said it would knock $50 per month off the cost of Zepbound for weight loss.

_____